logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9345787 B1

PDFFull Text
Expired
Date of Patent:
May. 24, 2016

Filed:

Dec. 21, 2009

Adenoviral vectors and methods and uses related thereto

Applicants:

Akseli Hemminki, Helsinki, FI;

Anna Kanerva, Helsinki, FI;

Vincenzo Cerullo, Helsinki, FI;

Sari Pesonen, Helsinki, FI;

Inventors:

Akseli Hemminki, Helsinki, FI;

Anna Kanerva, Helsinki, FI;

Vincenzo Cerullo, Helsinki, FI;

Sari Pesonen, Helsinki, FI;

Assignee:

Targovax Oy, Helsinki, FI;

Attorneys:

Cooley LLP

Ivor R. Elrifi

Matthew Pavao

Primary Examiner:

Michael Burkhart

Int. Cl.
CPC ...
C12N 15/00 (2006.01); A61K 48/00 (2006.01); A61K 31/7088 (2006.01); A61K 38/19 (2006.01); A61K 45/06 (2006.01); A61K 31/277 (2006.01); A61K 31/4188 (2006.01); A61K 31/661 (2006.01); A61N 5/10 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
A61K 48/005 (2013.01); A61K 31/277 (2013.01); A61K 31/4188 (2013.01); A61K 31/661 (2013.01); A61K 31/7088 (2013.01); A61K 38/193 (2013.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); C12N 15/86 (2013.01); A61N 2005/1098 (2013.01); C12N 2710/10021 (2013.01); C12N 2710/10043 (2013.01);
Abstract

The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing GM-CSF in a cell and increasing tumor specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing GM-CSF in a cell and increasing tumor specific immune response in a subject.

Find Patent Forward Citations

Loading…